Loring Wolcott & Coolidge Fiduciary Advisors LLP MA Trims Stake in Eli Lilly and Company (NYSE:LLY)

Loring Wolcott & Coolidge Fiduciary Advisors LLP MA lowered its position in Eli Lilly and Company (NYSE:LLY) by 3.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 7,195 shares of the company’s stock after selling 226 shares during the quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA’s holdings in Eli Lilly and Company were worth $6,413,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Pathway Financial Advisers LLC raised its stake in shares of Eli Lilly and Company by 92,759.9% in the third quarter. Pathway Financial Advisers LLC now owns 1,022,388 shares of the company’s stock valued at $905,774,000 after acquiring an additional 1,021,287 shares during the period. WD Rutherford LLC grew its holdings in shares of Eli Lilly and Company by 17.1% in the third quarter. WD Rutherford LLC now owns 274 shares of the company’s stock worth $243,000 after purchasing an additional 40 shares during the last quarter. Adell Harriman & Carpenter Inc. grew its holdings in shares of Eli Lilly and Company by 19.6% in the third quarter. Adell Harriman & Carpenter Inc. now owns 11,659 shares of the company’s stock worth $10,330,000 after purchasing an additional 1,910 shares during the last quarter. Childress Capital Advisors LLC grew its holdings in shares of Eli Lilly and Company by 4.5% in the third quarter. Childress Capital Advisors LLC now owns 2,445 shares of the company’s stock worth $2,166,000 after purchasing an additional 105 shares during the last quarter. Finally, Highview Capital Management LLC DE grew its holdings in shares of Eli Lilly and Company by 2.7% in the third quarter. Highview Capital Management LLC DE now owns 6,763 shares of the company’s stock worth $5,992,000 after purchasing an additional 181 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on LLY shares. Barclays upped their price target on shares of Eli Lilly and Company from $913.00 to $1,025.00 and gave the stock an “overweight” rating in a report on Wednesday, July 10th. Evercore ISI upgraded shares of Eli Lilly and Company to a “hold” rating in a report on Thursday, September 5th. Truist Financial increased their target price on shares of Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the stock a “buy” rating in a report on Thursday, October 10th. Wells Fargo & Company increased their target price on shares of Eli Lilly and Company from $875.00 to $1,000.00 and gave the stock an “overweight” rating in a report on Friday, August 9th. Finally, Berenberg Bank increased their target price on shares of Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the stock a “buy” rating in a report on Wednesday, August 14th. Three investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to MarketBeat, Eli Lilly and Company presently has an average rating of “Moderate Buy” and an average price target of $1,013.41.

Eli Lilly and Company Stock Down 6.3 %

NYSE:LLY opened at $846.90 on Thursday. The stock has a market capitalization of $804.90 billion, a P/E ratio of 124.73, a P/E/G ratio of 3.24 and a beta of 0.42. The company has a debt-to-equity ratio of 1.74, a quick ratio of 0.87 and a current ratio of 1.11. The company’s 50-day simple moving average is $916.20 and its 200-day simple moving average is $865.10. Eli Lilly and Company has a fifty-two week low of $547.61 and a fifty-two week high of $972.53.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Wednesday, October 30th. The company reported $1.18 EPS for the quarter, missing the consensus estimate of $1.53 by ($0.35). The company had revenue of $11.44 billion during the quarter, compared to analysts’ expectations of $12.09 billion. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. The business’s revenue for the quarter was up 20.4% compared to the same quarter last year. During the same period in the previous year, the business earned $0.10 earnings per share. On average, equities analysts anticipate that Eli Lilly and Company will post 14.05 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be given a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 0.61%. The ex-dividend date is Friday, November 15th. Eli Lilly and Company’s payout ratio is currently 76.58%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.